PE20010205A1 - Derivados 3-sustituido de 2-carboxiciclopropil glicina como agonistas de glutamato - Google Patents

Derivados 3-sustituido de 2-carboxiciclopropil glicina como agonistas de glutamato

Info

Publication number
PE20010205A1
PE20010205A1 PE2000000525A PE0005252000A PE20010205A1 PE 20010205 A1 PE20010205 A1 PE 20010205A1 PE 2000000525 A PE2000000525 A PE 2000000525A PE 0005252000 A PE0005252000 A PE 0005252000A PE 20010205 A1 PE20010205 A1 PE 20010205A1
Authority
PE
Peru
Prior art keywords
carboxyclopropyl
glycine
alkyl
lil
substituted derivatives
Prior art date
Application number
PE2000000525A
Other languages
English (en)
Inventor
Tercero Maria Concepcion Pedregal
Cano Ivan Collado
Garcia Maria Rosario Gonzalez
Llorente Alicia Marcos
De Uralde Garmendia Beatriz Lopezz
Melendo Ana Belen Bueno
Original Assignee
Lilly Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Sa filed Critical Lilly Sa
Publication of PE20010205A1 publication Critical patent/PE20010205A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/28—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and containing rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A DERIVADOS 3-SUSTITUIDO DE 2-CARBOXICICLOPROPIL GLICINA DE FORMULA I, DONDE: R1 ES HALO-ALQUILO C1-C10, HALO-ALQUENILO C2-C10, (CH2)nY, SH, S(O)pR4, S(O)3H, NH2, NHR5, NR6R7, NHCOR8, NO2, CO2H, CONHR9, 1H-TETRAZO-5-LIL, 5-FENILTETRAZO-1-LIL, PO3H2; n ES 1-2, Y ES OH, CN, N3, OR3; R5, R6, R7, R8, R9 SON ALQUILO C1-C4, ARILO, ARIL-ALQUILO C1-C4, 1H-TETRAZO-5-LIL, CARBOXI-ALQUILO C1-C4, 1H-TETRAZO-5-LIL-ALQUILO C1-C4; p ES 0-3. SON COMPUESTOS PREFERIDOS (2SR, 1`SR, 2'SR, 3'SR)-2-[(3'(2''-HIDROXIETIL)-2'-CARBOXI)CICLOPROPIL]GLICINA, (2SR, 1RS, 2'RS, 3'RS)-2-[3'-MERCAPTOMETIL-2'-CARBOXICICLOPROPIL]GLICINA, (2S,1'S,2'R,3'R)-2-(3'-HIDROXIMETIL-2'-CARBOXICICLOPROPIL)GLICINA, ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION Y A COMPUESTOS INTERMEDIOS. LOS COMPUESTOS I SON AGONISTAS DE GLUTAMATO EN LOS RECEPTORES METABOTROPICOS Y PUEDEN SER UTILES PARA EL TRATAMIENTO DE DESORDENES DEL SISTEMA NERVIOSO CENTRAL COMO ENFERMEDADES NEUROLOGICAS, NEURODEGENERATIVAS
PE2000000525A 1999-06-03 2000-05-31 Derivados 3-sustituido de 2-carboxiciclopropil glicina como agonistas de glutamato PE20010205A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99500090 1999-06-03

Publications (1)

Publication Number Publication Date
PE20010205A1 true PE20010205A1 (es) 2001-03-16

Family

ID=8242502

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000000525A PE20010205A1 (es) 1999-06-03 2000-05-31 Derivados 3-sustituido de 2-carboxiciclopropil glicina como agonistas de glutamato

Country Status (6)

Country Link
US (1) US6498180B1 (es)
EP (1) EP1189873A1 (es)
AU (1) AU5073600A (es)
CO (1) CO5180545A1 (es)
PE (1) PE20010205A1 (es)
WO (1) WO2000075101A1 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2849025B1 (fr) * 2002-12-20 2005-10-14 Rhodia Chimie Sa Esters d'allyle substitue par un groupe difluoromethylene, leur procede de synthese et leur utilisation
US7125871B2 (en) * 2000-05-31 2006-10-24 Eli Lilly And Company Excitatory amino acid receptor modulators
US7081481B2 (en) * 2000-05-31 2006-07-25 Eli Lilly And Company Excitatory amino acid receptor modulators
EP2275095A3 (en) 2005-08-26 2011-08-17 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
CA2625153A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
JP2009513672A (ja) 2005-10-31 2009-04-02 ブレインセルス，インコーポレイティド 神経発生のｇａｂａ受容体媒介調節
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
TWI417095B (zh) 2006-03-15 2013-12-01 Janssen Pharmaceuticals Inc １，４-二取代之３-氰基-吡啶酮衍生物及其作為ｍＧｌｕＲ２-受體之正向異位性調節劑之用途
EP2021000A2 (en) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenesis by modulating angiotensin
CA2651862A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
AU2007292848A1 (en) 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
RS51660B (en) 2007-09-14 2011-10-31 Ortho-Mcneil-Janssen Pharmaceuticals Inc. 1`, 3`-DISUPSTITUATED-4-PHENYL-3,4,5,6-TETRAHYDRO-2H, 1`H- [1,4`] BIPYRIDINYL-2`-ONE
KR20100080597A (ko) * 2007-09-14 2010-07-09 오르토-맥닐-얀센 파마슈티칼스 인코포레이티드 １,３-이치환된-４-페닐-1ｈ-피리딘-2-온
ES2365966T3 (es) 2007-09-14 2011-10-14 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. 4-(aril-x-fenil)-1h-piridin-2-onas 1,3-disustituidas.
RU2492170C9 (ru) 2007-11-14 2013-12-27 Орто-Макнейл-Янссен Фармасьютикалз, Инк. Имидазо[1,2-а]пиридиновые производные и их применение в качестве положительных аллостерических модуляторов рецепторов mglur2
RU2510396C2 (ru) 2008-09-02 2014-03-27 Янссен Фармасьютикалз, Инк. 3-азабицикло[3.1.0]гексильные производные в качестве модуляторов метаботропных глутаматных рецепторов
US8697689B2 (en) 2008-10-16 2014-04-15 Janssen Pharmaceuticals, Inc. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
CN102232074B (zh) 2008-11-28 2014-12-03 奥梅-杨森制药有限公司 作为代谢性谷氨酸盐受体调节剂的吲哚和苯并噁嗪衍生物
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
US8946205B2 (en) 2009-05-12 2015-02-03 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
KR101753826B1 (ko) 2009-05-12 2017-07-04 얀센 파마슈티칼즈, 인코포레이티드 1,２,４―트리아졸로［４,３―ａ］피리딘 유도체 및 신경정신 질환의 치료 또는 예방을 위한 이들의 용도
JP5852665B2 (ja) 2010-11-08 2016-02-03 ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド １，２，４−トリアゾロ［４，３−ａ］ピリジン誘導体およびｍＧｌｕＲ２受容体のポジティブアロステリックモジュレーターとしてのそれらの使用
AU2011328203B2 (en) 2010-11-08 2015-03-19 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
EP2649069B1 (en) 2010-11-08 2015-08-26 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
AU2014211727B2 (en) * 2013-02-04 2018-07-26 Prexton Therapeutics Sa Positive allosteric modulators of mGluR3
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
UA127921C2 (uk) 2014-01-21 2024-02-14 Янссен Фармацевтика Нв Комбінації, які містять позитивні алостеричні модулятори або ортостеричні агоністи метаботропного глутаматергічного рецептора 2 підтипу, та їх застосування
NZ722385A (en) 2014-01-21 2019-11-29 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3481975B2 (ja) * 1992-09-08 2003-12-22 サントリー株式会社 （２ｓ，１’ｓ，２’ｒ）−２−（２−カルボキシ−３−置換オキシメチルシクロプロピル）グリシン及びその製造法
JPH08301825A (ja) 1995-03-07 1996-11-19 Suntory Ltd ３’−置換−（２−カルボキシシクロプロピル）グリシン
IT1276153B1 (it) 1995-11-17 1997-10-27 Roberto Pellicciari Derivati di glicina ad attivita' antagonista dei recettori metabotropi del glutammato
EP0913389A4 (en) 1996-06-28 2000-02-02 Nippon Chemiphar Co CYCLOPROPYLGLYCINE DERIVATIVES AND AGONISTS OF THE L-GLUTAMATE RECEPTOR TYPE OF METABOLITE REGULATION
ES2131463B1 (es) 1997-04-08 2000-03-01 Lilly Sa Derivados de ciclopropilglicina con propiedades farmaceuticas.

Also Published As

Publication number Publication date
CO5180545A1 (es) 2002-07-30
US6498180B1 (en) 2002-12-24
WO2000075101A1 (en) 2000-12-14
AU5073600A (en) 2000-12-28
EP1189873A1 (en) 2002-03-27

Similar Documents

Publication Publication Date Title
PE20010205A1 (es) Derivados 3-sustituido de 2-carboxiciclopropil glicina como agonistas de glutamato
PE20080947A1 (es) Derivados de n-(amino-heteroaril)-1h-indol-2-carboxamidas como antagonistas de receptores de tipo trpv1
PE20040775A1 (es) DERIVADOS DE INDOL COMO AGONISTAS DE ADRENORECEPTORES ß2
CR7510A (es) DERIVADOS DE [1-4] DIAZEPINO[6,7,1-iJ)] QUINOLONA COMO AGENTES ANTIPSICOTICOS Y CONTRA LA OBESIDAD
PE20020911A1 (es) Derivados de indol como agonistas de 5ht2
CZ20032798A3 (cs) Nové pouzití slouceniny peptidové trídy pro lécbuallodynie nebo dalsích odlisných typu chronické nebo fantomové bolesti
CR6616A (es) Nuevos derivados de biarileter utiles como inhibidores de la recaptacion de monoaminas
BRPI0820112B8 (pt) derivados de isoxazol-piridina, seu uso e processos de preparação e medicamento
UY28144A1 (es) Agentes terapéuticos
LU92204I2 (fr) Dapoxetine sous toutes ses formes protégées par lebrevet de base
CY1106645T1 (el) Παραγωγα 1,2,4 τριαμινοβενζολης χρησιμα για τη θεραπευτικη αντιμετωπιση διαταραχων του κεντρικου νευρικου συστηματος
CY1109734T1 (el) Ενωσεις για τη θεραπευτικη αντιμετωπιση της σχιζοφρενειας και/ή διαταραχων της ρυθμισης της γλυκοζης
BRPI0418099A (pt) compostos, composição farmacêutica, e uso de um composto
RU94030812A (ru) Производные фосфоноянтарной кислоты, способ их получения и содержащие эти соединения фармацевтические композиции
BR0314488A (pt) Composto, composição farmacêutica e métodos de tratamento
EA200300854A1 (ru) Применение обратных агонистов гамка в комбинации с частичными агонистами никотиновых рецепторов, эстрогеном, избирательными модуляторами эстрогена или витамином е для лечения познавательных расстройств
ES2069330T3 (es) Derivados de hidrazona, su preparacion y uso.
ES2291454T3 (es) Utilizacion de carbamatos para prevenir o tratar trastornos del movimiento.
AR053206A1 (es) Derivados de isoindoles, composiciones farmaceuticas que los contienen, sus utilizaciones terapeuticas como inhibidores de la actividad de la proteina chaperona hsp90 y su empleo en la preparacion de medicamentos para el tratamiento de diversos tipos de cancer.
ES2133324T3 (es) Compuestos de dibenzoxazepina sustituidos, composiciones farmaceuticas y metodos de uso.
EA199900161A1 (ru) Производные пиридазино [4,5-в]-хинолин-5-оксида, их получение и применение в качестве антагонистов глицина
BR0311593A (pt) Derivados de 1-sulfonil-4-aminoalcoxi indol como moduladores de receptor 5-ht6 para tratamento dos distúrbios de snc
UY28377A1 (es) Agentes terapeuticos
AR035750A1 (es) Uso de n- (piridinilamino) indoles para la preparacion de medicamentos para el tratamiento de enfermedades o trastornos desmielinizantes
PE20021016A1 (es) Conjugados de pregabalina-lactosa

Legal Events

Date Code Title Description
FC Refusal